InflaRx
Renfeng Guo is currently serving as the CSO and Co-Founder at InflaRx Gmbh since January 2008. Previously, Renfeng has been an Adjunct Associate Professor at the University of Michigan Medical School since February 1998. Renfeng holds a Post-doc degree in Inflammation & immunology from the University of Michigan Medical School, an M.D. in Oncology from Norman Bethune University of Medical Sciences, and an M.S. in Cancer Immunology from Beijing Institute of Radiation Medicine.
This person is not in any offices
InflaRx
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.